Free Trial
NASDAQ:SCNI

Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

$3.46
-0.33 (-8.58%)
(As of 10:56 AM ET)
Today's Range
$3.24
$3.75
50-Day Range
$3.79
$5.20
52-Week Range
$0.39
$4.45
Volume
3,708 shs
Average Volume
24,690 shs
Market Capitalization
$6.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SCNI stock logo

About Scinai Immunotherapeutics Stock (NASDAQ:SCNI)

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

SCNI Stock Price History

SCNI Stock News Headlines

Scinai Immunotherapeutics Ltd ADR SCNI
Scinai leadership to attend BIO-Europe Spring 2024
Scinai Immunotherapeutics Ltd ADR
Scinai Immunotherapeutics Ltd. ADR
Scinai Immunotherapeutics Ltd ADR (SCNI)
See More Headlines
Receive SCNI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:SCNI
Previous Symbol
NASDAQ:SCNI
Employees
33
Year Founded
N/A

Profitability

Net Income
$-5,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.94) per share

Miscellaneous

Free Float
1,755,000
Market Cap
$7.09 million
Optionable
Not Optionable
Beta
2.45
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Amir Reichman M.B.A. (Age 48)
    M.Sc., CEO & Director
    Comp: $562.5k
  • Mr. Elad Mark B.Sc. (Age 41)
    Eng., M.B.A., Chief Operating Officer
    Comp: $277.02k
  • Dr. Tamar Ben-Yedidia Ph.D. (Age 60)
    Chief Science Officer
    Comp: $314.92k
  • Mr. Uri Ben-Or CPA (Age 54)
    CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $582k
  • Dr. Dalit Weinstein Fischer Ph.D.
    Chief Technology Officer
  • Mr. Joshua E. Phillipson B.Sc.
    M.B.A., Director of Communications & Investor Relations
  • Liat Halpert
    Head of Business Development & Sales
  • Merav Kamensky
    Head of Quality Control

SCNI Stock Analysis - Frequently Asked Questions

How have SCNI shares performed in 2024?

Scinai Immunotherapeutics' stock was trading at $5.9540 at the start of the year. Since then, SCNI shares have decreased by 41.8% and is now trading at $3.4649.
View the best growth stocks for 2024 here
.

When did Scinai Immunotherapeutics' stock split?

Scinai Immunotherapeutics's stock reverse split on the morning of Tuesday, May 21st 2024. The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Scinai Immunotherapeutics?

Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SCNI) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners